SCHEMBL21624

SCHEMBL21624

COC1CCN(c2ccccc2F)CC1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
ALDH1A1 P00352 3/20 0.49
HSD17B10 Q99714 1/20 0.47
KDM4E B2RXH2 6/20 0.45
TSHR P16473 4/20 0.45
POLB P06746 1/20 0.45
TDP1 Q9NUW8 2/20 0.44
GAA P10253 1/20 0.44
GLA P06280 1/20 0.43
LMNA P02545 2/20 0.43
ALOX15 P16050 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14689801 0.82 HSD17B10 (0.51) NOTUMSMN1; SMN2ALDH1A1HSD17B10KDM4E
SCHEMBL12093606 0.81 ADRB1 (0.53) SMN1; SMN2ALDH1A1TSHRGAALMNA
SCHEMBL1057318 0.81 ADRB1 (0.50) NOTUMSMN1; SMN2ALDH1A1HSD17B10KDM4E
SCHEMBL5460658 0.80 GAA (0.62) NOTUMSMN1; SMN2ALDH1A1HSD17B10KDM4E
SCHEMBL23368563 0.79 GAA (0.67) ALDH1A1HSD17B10KDM4EPOLBGAA
SCHEMBL15676577 0.78 NOTUM (0.42) NOTUMSMN1; SMN2KDM4EMAPK1
SCHEMBL30149942 0.78 NOTUM (0.42) NOTUMSMN1; SMN2KDM4EMAPK1
SCHEMBL28382978 0.78 NOTUM (0.38) NOTUMSMN1; SMN2ALDH1A1HSD17B10KDM4E
SCHEMBL14566099 0.77 NOTUM (0.57) NOTUMSMN1; SMN2ALDH1A1HSD17B10KDM4E
SCHEMBL377688 0.77 NOTUM (0.53) NOTUMSMN1; SMN2ALDH1A1HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 990 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116606338-A 6' -cyano modified locked nucleosides, nucleotides and nucleic acid polymers 中国人民解放军军事科学院军事医学研究院 2023-08-18 CN claimed
US-20230192751-A1 METHOD FOR THE PREPARATION OF OLIGONUCLEOTIDES THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV (CA) 2023-06-22 US claimed
EP-3119789-B1 BICYCLIC CARBOCYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM IONIS PHARMACEUTICALS INC (US) 2020-04-22 EP claimed
US-10287313-B2 RNA monomers containing 0-acetal levulinyl ester groups and their use in RNA microarrays THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2019-05-14 US claimed
EP-3323414-A1 INHIBITORS OF NEDD8-ACTIVATING ENZYME Millennium Pharmaceuticals, Inc. (US) 2018-05-23 EP claimed
EP-2850092-B1 TRICYCLIC NUCLEIC ACID ANALOGS IONIS PHARMACEUTICALS INC (US) 2017-03-01 EP claimed
US-20160340382-A1 RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2016-11-24 US claimed
EP-2727915-B1 Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof CONCERT PHARMACEUTICALS INC (US) 2016-04-13 EP claimed
EP-2334692-B1 RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS UNIV MCGILL (CA) 2016-04-13 EP claimed
EP-2580228-B1 SUBSTITUTED 2'-AMINO AND 2'-THIO-BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM IONIS PHARMACEUTICALS INC (US) 2016-03-23 EP claimed
US-20060173199-A1 Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses HONG BORCHERNG 2006-08-03 US claimed
EP-1594835-A2 METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES Auspex Pharmaceuticals, Inc. (US) 2005-11-16 EP claimed
EP-1589028-A2 Modified oligonucleotides, their preparation and their use Aventis Pharma Deutschland GmbH (DE) 2005-10-26 EP claimed
WO-2004064745-A2 METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES AUSPEX PHARMACEUTICALS, INC. (US) 2004-08-05 WO claimed
US-5789562-A STABLE HYBRIDIZATION COMPLEXES WITH NUCLEI ACIDS HOECHST AKTIENGESELLSCHAFT (DE) 1998-08-04 US claimed
US-5721350-A Deuterated nucleosides CHATTOPADHYAYA JYOTI (SE) 1998-02-24 US claimed
EP-0710667-A2 Modified oligonucleotides, their preparation and their use HOECHST AKTIENGESELLSCHAFT (DE) 1996-05-08 EP claimed
EP-0680969-A2 Modified oligonucleotides, their preparation and their use HOECHST AKTIENGESELLSCHAFT (DE) 1995-11-08 EP claimed
EP-0648220-A1 DEUTERATED NUCLEOSIDES CHATTOPADHYAYA, Jyoti (SE) 1995-04-19 EP claimed
WO-1993025566-A1 DEUTERATED NUCLEOSIDES CHATTOPADHYAYA JYOTI (SE) 1993-12-23 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10287313-B2 RNA monomers containing 0-acetal levulinyl ester groups and their use in RNA microarrays EFTUD2, RNMT, NSUN2 NOTUM 1889/4885SMN1; SMN2 905/4885ALDH1A1 199/4885
US-20160340382-A1 RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS EFTUD2, RNMT, RNGTT NOTUM 2025/4885SMN1; SMN2 1087/4885ALDH1A1 212/4885
US-20060173199-A1 Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses LSS, DHPS, CYP51A1 NOTUM 256/4885SMN1; SMN2 4543/4885ALDH1A1 1435/4885
US-20230192751-A1 METHOD FOR THE PREPARATION OF OLIGONUCLEOTIDES POLN, POLRMT, POLI NOTUM 4122/4885SMN1; SMN2 1452/4885ALDH1A1 4284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.